Hypera S.A. (HYPMY)
OTCMKTS · Delayed Price · Currency is USD
4.600
+0.023 (0.50%)
Nov 7, 2025, 2:15 PM EST
Hypera Revenue
Hypera had revenue of 2.23B BRL in the quarter ending September 30, 2025, with 16.25% growth. This brings the company's revenue in the last twelve months to 6.97B, down -10.35% year-over-year. In the year 2024, Hypera had annual revenue of 7.44B, down -5.97%.
Revenue (ttm)
6.97B BRL
Revenue Growth
-10.35%
P/S Ratio
2.23
Revenue / Employee
665.31K BRL
Employees
10,481
Market Cap
2.92B USD
Revenue Chart
* This company reports financials in BRL.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.44B | -472.19M | -5.97% |
| Dec 31, 2023 | 7.91B | 368.30M | 4.88% |
| Dec 31, 2022 | 7.55B | 1.61B | 27.10% |
| Dec 31, 2021 | 5.94B | 1.85B | 45.21% |
| Dec 31, 2020 | 4.09B | 794.12M | 24.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Chrome Holding Co. | 174.90M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 2.61M |
Hypera News
- 9 days ago - Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Brazil's Hypera announces new majority stakeholder group - Reuters
- 8 months ago - Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Hypera: Short-Term Pain For Long-Term Gain - Seeking Alpha
- 5 years ago - Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio - Seeking Alpha
- 5 years ago - A Brazilian-Focused Dividend Portfolio - Seeking Alpha